Lite Strategy (LITS) Market Capitalization (2010 - 2026)
Lite Strategy (LITS) posted Market Capitalization of $40.8 million for Q1 2026, down 15.04% on a QoQ basis from $48.0 million in Q4 2025, and up 179.48% year-over-year from $14.6 million in Q1 2025.
Analysis
Lite Strategy (LITS) Market Capitalization (2010 - 2026) Analysis & Trends
Lite Strategy has reported Market Capitalization for 17 years, with the latest figure at $40.8 million in Q1 2026.
- On a quarterly basis, Market Capitalization rose 179.48% year-over-year to $40.8 million in Q1 2026; TTM through Mar 2026 was $40.8 million, a 179.48% increase from a year earlier, with the FY2025 full-year figure at $16.5 million, down 15.12% from the prior year.
- Market Capitalization was $40.8 million for Q1 2026 at Lite Strategy, down from $48.0 million in the prior quarter.
- The five-year high for Market Capitalization was $81.2 million in Q2 2022, with the low at $14.6 million in Q1 2025.
- Average Market Capitalization over 5 years is $39.9 million, with a median of $38.6 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Market Capitalization plunged 90.99% in 2022, then soared 275.63% in 2025.
- Over 5 years, Market Capitalization stood at $32.0 million in 2022, then rose by 20.83% to $38.6 million in 2023, then plunged by 57.59% to $16.4 million in 2024, then jumped by 192.83% to $48.0 million in 2025, then declined by 15.04% to $40.8 million in 2026.
- The last three Market Capitalization figures came in at $40.8 million (Q1 2026), $48.0 million (Q4 2025), and $71.3 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 40.78 Mn |
| Dec 31, 2025 | 48.00 Mn |
| Sep 30, 2025 | 71.33 Mn |
| Jun 30, 2025 | 16.46 Mn |
| Mar 31, 2025 | 14.59 Mn |
| Dec 31, 2024 | 16.39 Mn |
| Sep 30, 2024 | 18.99 Mn |
| Jun 30, 2024 | 19.39 Mn |
| Mar 31, 2024 | 26.65 Mn |
| Dec 31, 2023 | 38.65 Mn |
| Sep 30, 2023 | 46.71 Mn |
| Jun 30, 2023 | 43.84 Mn |
| Mar 31, 2023 | 30.65 Mn |
| Dec 31, 2022 | 31.98 Mn |
| Sep 30, 2022 | 51.97 Mn |
| Jun 30, 2022 | 81.22 Mn |
| Mar 31, 2022 | 79.89 Mn |
| Dec 31, 2021 | 354.86 Mn |
| Sep 30, 2021 | 310.99 Mn |
| Jun 30, 2021 | 320.95 Mn |